U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18O2
Molecular Weight 278.345
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAY-36-7620

SMILES

C=C1C[C@@H]2COC(=O)[C@]2(CC3=CC=C4C=CC=CC4=C3)C1

InChI

InChIKey=CVIRWLJKDBYYOG-MJGOQNOKSA-N
InChI=1S/C19H18O2/c1-13-8-17-12-21-18(20)19(17,10-13)11-14-6-7-15-4-2-3-5-16(15)9-14/h2-7,9,17H,1,8,10-12H2/t17-,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H18O2
Molecular Weight 278.345
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

BAY-36-7620 is a potent and selective antagonist at mGlu1receptors and inhibits >60% of mGlu1a receptor constitutive activity (IC50 = 0.38 uM). BAY-36-7620 is thus the first described mGlu1 receptor inverse agonist. It impairs classical conditioning and associated synaptic plasticity in hippocampal neurons. BAY-36-7620 exhibits neuroprotective and anticonvulsive effects in vivo following systemic administration.

CNS Activity

Curator's Comment: BAY-36-7620 has good BBB penetration. BAY-36-7620 was found to be anticonvulsant following systemic administration.

Originator

Curator's Comment: # Bayer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.16 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Glutamate metabotropic receptors as targets for drug therapy in epilepsy.
2003-08-22
[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists.
2003-05
Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620.
2001-10-05
BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity.
2001-05
Patents

Sample Use Guides

Mice: BAY-36-7620 was given i.p. once a day, at a single dose level of 10 mg/kg. Treatment of mice bearing MDA-MB-231 xenografts with BAY-36-7620, by intraperitoneal injection, resulted in a significant reduction in tumor volume of up to 80%.
Route of Administration: Intraperitoneal
To test for an antagonistic effect of BAY-36-7620 on mGlu1 or mGlu5 receptors, HEK 293 cells were stimulated with a Glu concentration around its EC50 value (1 uM for mGlu1a & 5 uM for mGlu5a), in the presence of BAY-36-7620, applied at a concentration of 0.1 or 10 uM. A strong inhibition of the Glu effect (61 ± 3 % inhibition) was observed with 0.1 uM BAY-36-7620 and a total inhibition was observed with 10 uM BAY-36-7620 on mGlu1 receptors whereas no effect was seen on mGlu5 receptors. The antagonist effect of BAY-36-7620 on mGlu1a receptors was concentration-dependent with an IC50 of 0.16 ± 0.01 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:49:17 GMT 2025
Edited
by admin
on Mon Mar 31 22:49:17 GMT 2025
Record UNII
0P934RSF8B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1H-CYCLOPENTA(C)FURAN-1-ONE, HEXAHYDRO-5-METHYLENE-6A-(2-NAPHTHALENYLMETHYL)-, (3AS,6AS)-
Preferred Name English
BAY-36-7620
Common Name English
Code System Code Type Description
PUBCHEM
9903757
Created by admin on Mon Mar 31 22:49:17 GMT 2025 , Edited by admin on Mon Mar 31 22:49:17 GMT 2025
PRIMARY
CAS
232605-26-4
Created by admin on Mon Mar 31 22:49:17 GMT 2025 , Edited by admin on Mon Mar 31 22:49:17 GMT 2025
PRIMARY
FDA UNII
0P934RSF8B
Created by admin on Mon Mar 31 22:49:17 GMT 2025 , Edited by admin on Mon Mar 31 22:49:17 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY